Zymeworks Inc.

ZYME Healthcare Biotechnology

Zymeworks Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.0 million, up 38.9% from fiscal 2024. In the quarter to June 2026, revenue fell 90.6%, EPS fell 2,166.7% and free cash flow fell 385.5%, each against the same quarter a year earlier.

25.07 0.68 −2.64%
Market cap
$1.8B
P/E
0.0×
Fwd P/E
16.2×
Dividend yield
—
F-score
7/9
Altman Z
11.56
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
9.62 18.74 23.01 51.39
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(41.20) (193.53) (40.90) (59.72)
P/B ratio
4.04 7.39 11.43 23.74
Price to Tangible BV
4.22 7.78 12.43 28.33
EV/Sales
7.92 16.58 18.52 44.11
EV/EBITDA
0.00 0.00 0.00 0.00
EV/Operating CF
(16.57) (53.23) (19.99) (13.72)
EV/FCF
(16.08) (49.69) (19.33) (13.49)
Quick Ratio
6.69 5.52 10.36 5.86
Current Ratio
6.94 5.88 10.82 6.32
Net Debt/EBITDA
12.90 5.42 8.24 6.74
Debt/Assets
0.00% 0.08% 0.06% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.30 0.26 0.18 0.09
Operating CF/Net income
1.60 0.25 1.04 0.71
Capex/Depreciation
(0.16) (0.36) (0.08) 0.00
Interest Coverage
— — (22.81) (6.40)
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
51.23% 613.60% 625.79% 421.24%
Intangible Assets out of Total Assets
0.03 0.04 0.03 0.03
Share Based Compensation of Revenue
25.03% 351.89% 288.00% 246.93%
Graham Net Nets
0.17 0.09 0.04 (0.01)
Graham Number
0.00 0.00 0.00 0.00
Earnings Yield
(4.92%) (4.10%) (5.47%) (7.73%)
Free Cash Flow Yield
(5.12%) (1.78%) (4.16%) (6.36%)
Revenue per Share
0.36 0.03 0.03 0.06
Operating CF per Share
(0.41) (0.14) (0.61) (0.44)
Capex per Share
(0.01) (0.01) 0.00 0.00
Free Cash Flow per Share
(0.42) (0.15) (0.62) (0.44)
Cash per Share
3.33 3.03 4.88 3.71
Shareholders Equity per Share
4.22 3.56 2.19 1.10
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
4.22 3.56 2.19 1.10
Free Cash Flow
(31.82) (10.98) (45.93) (31.95)
Working Capital
249.67 206.45 350.03 251.15
Capital Expenditures
(0.41) (0.72) (0.22) 0.00
Net Current Asset Value
214.51 170.74 71.05 (18.21)
EV/EBIT
0.00 0.00 0.00 0.00
Capex to Sales
0.01 0.29 0.09 0.00
Price to Operating Income
0.00 0.00 0.00 0.00
Other line items
Average Receivables
26.53 30.23 14.63 4.28
Average Payables
43.07 48.09 34.22 29.23
Average Assets
442.21 404.81 451.87 402.67
Average Common Equity
343.52 303.63 244.28 207.44

Fold the line items

Columns are period end dates